General Updates

Ref: 13/SE/LC/2026-27 Date: November 05, 2026 To, To, National Stock Exchange of India Limited BSE Limited (“BSE”) (“NSE”) Listing Department Listing Department Corporate Relationship Department Exchange Plaza, C-1 Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Complex Bandra (East), Mumbai – 400051 Dalal Street, Fort, Mumbai - 400 001 NSE Scrip Symbol: SMT BSE Scrip Code: 545001 ISIN: INE356Y01018 ISIN: INE356Y01018 Subject: Outcome of Board Meeting, pursuant to Regulation 30 read with Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015 (“Listing Regulations”) - Acquisition Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III and other applicable provisions of the Listing Regulations, we would like to inform you that, the Board of Directors of the Sahajanand Medical Technologies Limited (“Company”), at its meeting held today, i.e., November 05, 2026, have inter-alia considered, approved investment by Sahajanand Medical Technologies Ireland Limited, Wholly Owned Subsidiary of the Company, (“SMT Ireland”) in SNP Medical Corp. a US based corporation registered in Delaware. Details as required under Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, are enclosed herewith as Annexure A. The meeting commenced at 3:00 PM (IST) and concluded at 4:43 PM (IST). The above intimation is also available on the website of the Company at www.smtpl.com and on the website of BSE Limited and National Stock Exchange of India Limited. Kindly take the same on records. Thanking you, For Sahajanand Medical Technologies Limited Bhargav Dhirajlal Kotadia Managing Director & Chief Executive Officer DIN: 06575042 Annexure-A Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is as under: Sr. Particulars Details 1 Name of the target entity, details in brief such as size, SNP Medical Corp. (“SNP”) turnover etc.; Turnover of 2025: USD 3,00,000 2 Whether the acquisition would fall within related party Yes. transaction(s) Yes, Ms. Priyanka Cohen (Promotor & Whether the promoter/ promoter group/ group companies Non-Executive Director of the have any interest in the entity being acquired? If yes, nature Company) is a Director in SNP. of interest and details thereof and whether the same is done at “arm’s length”; The transaction is at Arm’s length basis. 3 Industry to which the entity being acquired belongs; Medical Device 4 Objects and impact of acquisition (including but not limited Diversification of product portfolio to, disclosure of reasons for acquisition of target entity, if within the existing main line of the its business is outside the main line of business of the listed business of the Company entity); 5 Brief details of any governmental or regulatory approvals Not Applicable required for the acquisition; 6 Indicative time period for completion of the acquisition; Tentatively the acquisition would be completed by 31st March, 2027 7 Consideration - whether cash consideration or share swap Cash Consideration or any other form and details of the same 8 Cost of acquisition and/or the price at which the shares are Acquisition cost is upto USD acquired; 7,80,000/- (Price per share will be determined based on valuation of SNP Medical Corporation) 9 Percentage of shareholding / control acquired and / or SMT Ireland holds 14.15% stake in number of shares acquired; SNP Medical Corporation as on 30th September 2026 and with this new acquisition, the percentage would increase upto 17.19%. 10 Brief background about the entity acquired in terms of SNP medical is a medical device products/line of business acquired, date of incorporation, startup based in the US and working on history of last 3 years turnover, country in which the developing Medical Device acquired entity has presence and any other significant information (in brief); It is a US based corporation registered in Delaware on May 31, 2022. Revenue details are as below for last three calendar years 2025: USD 3,00,000 2024: USD 2,34,960 2023: USD 5,64,930